Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(04): 24-27
DOI: 10.4103/0971-5851.57667
Original Article

Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial

Jyoti Bajpai
Department of Medical Oncology, BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
19 November 2021

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bhutani M, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncology 2002;19:141-150
  • 2 Kumar L. Chronic Myelogenous leukemia (CML): An update. Nat Med J India 2006;19:255-63
  • 3 Druker BJ, Guilhot F, O′Brien S, et al. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 2006;355:2408-2417.
  • 4 Mauro M, Deininger M. Chronic myeloid leukemia in 2006: a perspective. Hematologica. 2006;91:152-158.
  • 5 Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005:183-187.
  • 6 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
  • 7 Guilhot F, Apperley J, Kim D et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007 May 15;109(10):4143- 50.
  • 8 Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15;109(12):5143-50.
  • 9 Tokarski J, Newitt J, Lee F, et al. The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood. 2004;104:abstract 553
  • 10 Cortes J, Rousselot Ph, Kim D et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213
  • 11 Talpaz M,shahNP,Kantarjian H, et al.Dasatinib in imatinib resistant CML and Philadelphia chromosome positive leukemias. NEJM2006:354:2531-41
  • 12 Talpaz M, Apperley J. F., Kim D. W., et al. Dasatinib in patients with AP-CML who are resistant or intolerant to Cmatinib:results of the CA180005 ′START-A′study.Proc Am Soc Clin Oncol 2006:24;343a(Abstract 6526).
  • 13 Coutre S., Martinelli G., Dombret H. , et al . Dasatinib in patients with LB- CMLor Ph +ALL who are imatinib resistant or intolerant:the CA180015 ′START - L′ study. Proc Am Soc Clin Oncol 2006;24:6528.
  • 14 Estrov Z. , O′Brien S., Giles F., et al. Dasatinib, a dual Srcabl inhibitor, is active in Ph +CML following treatment with imatinib and AMN107. Proc Am Soc Clin Oncol 2006;24:344a (abstract 6530)
  • 15 Cortes J. E., Kim D. W., Rosti G., et al. Dasatinib in patients with CML- MBC who are imatinib resistant or intolerant: Results of the CA180006 ′START- B′ study. Proc Am Soc Clin Oncol 2006; 24:6529.
  • 16 Kantarjian H, O′Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;15;109(8):1556-60